Equillium director granted 70,000 stock options

Equillium, Inc. director Mark Pruzanski received a grant of stock options covering 70,000 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Equillium, Inc. director Mark Pruzanski received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.8400 per share and bring his directly held option position reported in this filing to 70,000 derivative securities.

According to the terms, the option vests in twelve equal monthly installments starting on the grant date of May 28, 2026, and will in any case be fully vested on the date of Equillium's annual meeting of stockholders following that grant date. The option expires on May 27, 2036.

Insider Trade Summary

Grant/Award: 70,000 shares

Grant/Award 1 txn

Insider Pruzanski Mark

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	70,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 70,000 contracts (Direct)

Footnotes (1)

F1. The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Key Figures

Option grant size: 70,000 options Exercise price: $2.8400 per share Total options after grant: 70,000 options +2 more

5 metrics

Option grant size 70,000 options Director stock option grant on May 28, 2026

Exercise price $2.8400 per share Exercise price for director stock option

Total options after grant 70,000 options Total derivative securities following transaction

Expiration date May 27, 2036 Option expiration for director grant

Vesting schedule 12 monthly installments Commencing on May 28, 2026, or fully at next annual meeting

Key Terms

Director Stock Option (right to buy), grant/award acquisition, derivative securities, vests in twelve equal monthly installments, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: "Director Stock Option (right to buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

derivative securities financial

"derivativeTransactionCount for all derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vests in twelve equal monthly installments financial

"The option vests in twelve equal monthly installments commencing on the grant date"

annual meeting of stockholders financial

"fully vested on the date of the Issuer's annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Equillium (EQ) director Mark Pruzanski report in this Form 4?

Mark Pruzanski reported receiving a grant of stock options for 70,000 shares of Equillium common stock. These options are compensation-related, carry an exercise price of $2.8400 per share, and are scheduled to vest over time as described in the grant terms.

How many Equillium (EQ) options did the director hold after the reported transaction?

After the reported transaction, Mark Pruzanski held 70,000 director stock options according to the Form 4. This figure reflects the derivative securities position shown in the filing following the grant, all relating to Equillium common stock underlying the option award.

What is the exercise price and expiration date of the new Equillium (EQ) options?

The newly granted Equillium options have an exercise price of $2.8400 per share and expire on May 27, 2036. This means the director can purchase Equillium common shares at that price any time before the stated expiration date, subject to vesting.

How do the Equillium (EQ) director stock options vest?

The director stock options vest in twelve equal monthly installments beginning on the grant date of May 28, 2026. However, they will be fully vested on the date of Equillium's annual meeting of stockholders following that grant date, even if monthly vesting is incomplete.

Is the Equillium (EQ) Form 4 transaction a market purchase or sale of shares?

The Form 4 reflects a grant or award of stock options, not an open-market purchase or sale. The transaction is coded as an acquisition of derivative securities, providing the right to buy Equillium common stock at a fixed exercise price in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/29/2026 - 06:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pruzanski Mark

(Last)

(First)

(Middle)

2223 AVENIDA DE LA PLAYA, SUITE 105

(Street)

LA JOLLA

CALIFORNIA

92037

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Equillium, Inc. [ EQ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$2.84	05/28/2026		A		70,000		⁽¹⁾	05/27/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

	/s/ Daniel M. Bradbury, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR